Tenaya therapeutics announces fda clearance to begin clinical testing of tn-401 gene therapy for the treatment of pkp2-associated arrhythmogenic right ventricular cardiomyopathy

Pkp2 mutations are the leading cause of arvc, a dangerous condition linked to sudden cardiac arrest in young people estimated to affect 70,000 people in the us
TNYA Ratings Summary
TNYA Quant Ranking